Isomorphic Keeps IsoDDE Closed

Keeping IsoDDE off the shelf turns it from a software product into a drug creation engine, which lets Isomorphic capture far more value per program and keep the best training data inside its own loop. In practice, pharma partners bring targets, assays, and development muscle, while Isomorphic runs the modeling, design, and optimization work as a hands on research collaborator instead of selling seats to scientists.

• This model matches how the company gets paid. Its collaborations with Lilly and Novartis were announced as multi target research deals with upfront payments and milestone economics, and the company describes partner funded discovery plus wholly owned programs as its two revenue channels, not software subscriptions.
  1 isomorphiclabs 2 isomorphiclabs 4 sacra
• The closed workflow is also a moat play. Experimental results from synthesis and assays feed back into the design loop, so each program can improve future performance. Making IsoDDE self service would give away more of that workflow, and more of the resulting data, to customers.
  4 sacra
• This puts Isomorphic closer to an AI native biotech than a tools vendor. A contrast is Schrödinger, which is explicitly deploying Bunsen inside Bristol Myers Squibb as software layered onto existing pharma workflows, while Isomorphic structures work as deeper co-development partnerships across targets and modalities.
  3 schrodinger 4 sacra 5 isomorphiclabs

The next step is a fuller shift from paid discovery collaborations into owning more drug assets. As the platform expands across small molecules, antibodies, peptides, and molecular glues, the biggest upside comes from using partner programs to fund model improvement, then carrying selected internal candidates further into development and keeping more of the downstream economics.